Gaithersburg, United States
The company’s novel approach to peptide and oligonucleotide delivery presents substantial potential for breakthroughs in the field of biotechnology. This technology could revolutionize the way these compounds are delivered and utilized, opening new possibilities in drug development and treatment methodologies.
Although there is no publicly available information about the last investment or the investors involved, OncoImmunin, Inc. clearly holds promise within the biotechnology sector. Its long-standing presence since 1994 indicates stability and resilience, while its focus on patented delivery technology suggests a commitment to innovation and advancement within the field.
